Product Description
Mechanisms of Action: Stem Cell Therapy
Novel Mechanism: No
Modality: Cell Therapy
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Anterogen
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Korea, United States
Active Clinical Trial Count: 4
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Diabetic Foot
Phase 2: Epidermolysis Bullosa Dystrophica
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| ALLO-ASC-DEB-201 | P2 |
Recruiting |
Epidermolysis Bullosa Dystrophica |
2025-10-01 |
12% |
2024-04-23 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
| ALLO-ASC-DFU-302 | P3 |
Active, not recruiting |
Diabetic Foot |
2024-12-05 |
20% |
2024-12-14 |
Primary Endpoints |
| ALLO-ASC-SHEET | P2 |
Recruiting |
Diabetic Foot |
2024-12-01 |
74% |
2023-08-25 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
| ALLO-ASC-SHEET-102 | P2 |
Completed |
Diabetic Foot |
2023-10-23 |
68% |
2025-01-24 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|